A recent study from the University of Pittsburgh has brought to light a crucial factor in determining the effectiveness of new anti-amyloid therapies for Alzheimer’s disease.
Published in Neurology, the medical journal of the American Academy of Neurology, this study emphasizes the importance of the severity of amyloid deposition in the brain over age in predicting the progression of Alzheimer’s disease.
The research, led by Dr. Oscar Lopez, professor of neurology at Pitt and chief of cognitive and behavioral neurology at UPMC, focuses on the buildup of amyloid beta (A-beta) clumps, a hallmark of Alzheimer’s disease pathology.
The study uniquely targets an older demographic, with participants enrolled at an average age of 85 and followed for up to 11 years, contrasting with previous studies that mostly examined younger populations.
The study observed that amyloid accumulation steadily increases over time in individuals, regardless of their initial amyloid status. However, this increase is notably faster in those aged 80 and above, explaining the higher prevalence of Alzheimer’s in this age group.
Interestingly, participants with positive amyloid brain scans at the study’s start developed dementia two years earlier than those without amyloid deposits, highlighting the role of early amyloid buildup in the disease’s progression.
Lopez’s team found that the short-term change in A-beta over approximately 1.8 years was not a reliable predictor of future dementia risk.
Instead, more significant factors were the severity of the initial amyloid burden and other brain damage markers, such as white matter lesions and decreased gray matter thickness.
These findings suggest that the pathological process of Alzheimer’s may already be active when such signs are first detected.
The study underscores that amyloid accumulation in the brain, a process that takes decades, occurs alongside other brain pathologies like small vessel disease.
While this study did not explore whether a vascular process occurs parallel to A-beta deposition, understanding the timing of these pathologies is crucial for future primary prevention therapies.
Dr. Lopez, who also directs Pitt’s Alzheimer’s Disease Research Center, points out that these findings align with other research indicating the long developmental period of amyloid accumulation and its co-occurrence with other brain conditions.
The study’s insights into the timing and severity of amyloid deposition provide a pivotal step forward in effectively implementing dementia treatments, particularly for older individuals.
This research highlights the potential of personalized treatment approaches, focusing on amyloid burden rather than age, to better manage and potentially delay the progression of Alzheimer’s disease.
If you care about Alzheimer’s, please read studies about Vitamin D deficiency linked to Alzheimer’s, vascular dementia, and Oral cannabis extract may help reduce Alzheimer’s symptoms.
For more information about brain health, please see recent studies about Vitamin B9 deficiency linked to higher dementia risk, and results showing flavonoid-rich foods could improve survival in Parkinson’s disease.
The research findings can be found in Neurology.
Copyright © 2023 Knowridge Science Report. All rights reserved.
